Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03386032 · ClinicalTrials.gov registry record · Phase 3
8-Week Atopic Dermatitis (AD) Treatment Study
A Phase 3 study, sponsored by Procter and Gamble.
- Completed
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
NCT03386032: Completed Phase 3 study, sponsored by Procter and Gamble.
NCT03386032 is a Phase 3 study that has completed, run by Procter and Gamble. The registered enrollment target is 65 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03386032, a Phase 3 study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a study to investigate the clinical effectiveness of the Sponsor's experimental cream treatment on eczema as measured by visual grading of SCORAD (scoring of atopic dermatitis).
Primary Outcome
SCORAD (Severity Scoring of Atopic Dermatitis) Change from Baseline to Week 8 of atopic dermatitis lesion as measured by the Scoring of Atopic Dermatitis (SCORAD). SCORAD is a composite severity index comprising a) the amount/extent of body area affected; b)b) 2 subjective symptom of pruritus (10 pts VAS) and sleep disturbance measured (10 pts VAS); and c) 6 disease intensity assessments \[Dryness/Scaling, Erythema, Excoriation, Induration/Papulation, Lichenification and Oozing/ Weeping/Crusting
Interventions
- OTHER Placebo Cream
- DRUG Investigational OTC Cream
- DRUG 0.05% Desonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2018-08-18 |
| Phase | Phase 3 |
What the finished NCT03386032 record still lists
NCT03386032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo Cream is the first listed.
NCT03386032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03386032 about?
NCT03386032 is a clinical study titled "8-Week Atopic Dermatitis (AD) Treatment Study". This is a study to investigate the clinical effectiveness of the Sponsor's experimental cream treatment on eczema as measured by visual grading of SCORAD (scoring of atopic dermatitis).
What is the current status of trial NCT03386032?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2017-11-27. Estimated completion is 2018-08-18.
What interventions are being tested in trial NCT03386032?
The interventions under investigation include: Placebo Cream (OTHER), Investigational OTC Cream (DRUG), 0.05% Desonide (DRUG).
Who is sponsoring clinical trial NCT03386032?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03386032's enrollment target sits among peer trials
65 1797th of 2000 higher than 202 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI